Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma

被引：0
作者：
Chang-Yu Chen
Yung-Song Lin
Chien-Ho Chen
Yin-Ju Chen
机构：
[1] Taipei Medical University,School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology
[2] The University of Tokyo,Department of Molecular Preventive Medicine, Graduate School of Medicine
[3] Taipei Medical University,Department of Otolaryngology, School of Medicine, College of Medicine
[4] Department of Otolaryngology,Department of Radiation Oncology
[5] Chi Mei Medical Center,Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering
[6] Taipei Medical University Hospital,International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering
[7] Taipei Medical University,School of Biomedical Engineering, College of Biomedical Engineering
[8] Taipei Medical University,undefined
[9] Taipei Medical University,undefined
来源：
Journal of Biomedical Science | / 25卷
关键词：
Annexin A2 (ANXA2); Nasopharyngeal carcinoma (NPC); Cancer progression; Therapeutic resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Nasopharyngeal carcinoma (NPC) is a head and neck cancer with poor clinical outcomes and insufficient treatments in Southeast Asian populations. Although concurrent chemoradiotherapy has improved recovery rates of patients, poor overall survival and low efficacy are still critical problems. To improve the therapeutic efficacy, we focused on a tumor-associated protein called Annexin A2 (ANXA2). This review summarizes the mechanisms by which ANXA2 promotes cancer progression (e.g., proliferation, migration, the epithelial-mesenchymal transition, invasion, and cancer stem cell formation) and therapeutic resistance (e.g., radiotherapy, chemotherapy, and immunotherapy). These mechanisms gave us a deeper understanding of the molecular aspects of cancer progression, and further provided us with a great opportunity to overcome therapeutic resistance of NPC and other cancers with high ANXA2 expression by developing this prospective ANXA2-targeted therapy.
引用
收藏
相关论文
共 666 条
  • [1] Sun LM(2005)Trends in the incidence rates of nasopharyngeal carcinoma among Chinese Americans living in Los Angeles County and the San Francisco metropolitan area, 1992-2002 Am J Epidemiol 162 1174-1178
  • [2] Epplein M(2007)Nasopharyngeal carcinoma: molecular biomarker discovery and progress Mol Cancer 6 1-31
  • [3] Li CI(2005)Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma Cancer 103 22-52
  • [4] Vaughan TL(2013)Emerging treatment options for nasopharyngeal carcinoma Drug Des Devel Ther 7 37-477
  • [5] Weiss NS(2010)Treatment approaches to nasopharyngeal carcinoma: a review Anti-Cancer Drugs 21 471-774
  • [6] Cho WC(2012)Nasopharyngeal carcinoma: salvage of local recurrence Oral Oncol 48 768-26959
  • [7] Ma BB(2015)Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis Med Oncol 32 392-1211
  • [8] Chan AT(2015)Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma Oncotarget 6 26946-14360
  • [9] Zhang L(2013)Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis Oncotarget 4 1199-3801
  • [10] Chen QY(2011)Annexin A2 promotes glioma cell invasion and tumor progression J. Neurosci. Off. J. Soc. Neurosci 31 14346-156
12345678910